Dr. Hadley W. Wyre, MD

Dr. Wyre practices at The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System.

Dr. Wyre's NPI, 1093993115, was assigned on January 31, 2008. Dr. Wyre graduated from Emory University School of Medicine in 2006. Dr. Wyre holds Kansas license 04-35672.

Dr. Wyre's primary practice is The University of Kansas Hospital, at 4000 Cambridge Street, Kansas City, KS 66160 in Wyandotte County. The practice phone is (913) 588-5000.

Dr. Wyre's primary practice is The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System. Dr. Wyre is also affiliated with University Health Truman Medical Center. The medical group on file is Kansas University Physicians. Dmand AI also links Dr. Wyre to 1 more hospital, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wyre practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Wyre's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Wyre's licenses on file in 2 states: Kansas and Missouri.

CMS data shows 607 Medicare services from Dr. Wyre across 8 procedure codes in 2024, for 321 Medicare patients. Medicare paid $50,513 for them.

CMS counts 321 Medicare patients who saw Dr. Wyre in 2024. The largest group is 65 to 74, with 155 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wyre's median patient age at 72, with 30% women.

In 2024, Dr. Wyre wrote 461 Medicare Part D claims for 118 patients. 96% of them were for generic drugs. CMS names the drug for 260 of them, across 8 drugs with 11 or more claims each, at $14,871 in total drug cost. In 2023, CMS named 221 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Wyre for performance year 2024, reported through an alternative payment model (APM). Dr. Wyre accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wyre as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Wyre, published from 2013 to 2025. 2015 was the busiest year, with 2. The most frequent topics are Cystectomy, Urinary Bladder Neoplasms and Pilot Projects. Dr. Wyre has published most often in Bladder Cancer. Dr. Wyre's most frequent co-authors are Eugene Kang Lee, MD, David A. Duchene, MD and Philip Andre Fontenot, MD.

Dmand AI links Dr. Wyre to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms and Heartburn.

CMS Open Payments shows 10 general payments to Dr. Wyre from 8 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Ethicon Inc. paid the most, $179.

Dr. Wyre graduated from Emory University School of Medicine in 2006.